Immune Biomarkers of Islet Transplant Rejection Revealed by Synthetic Immunological Niche.
- 1Department of Biomedical Engineering, University of Michigan, Ann Arbor, USA.
- 2Department of Pediatrics, Department of Molecular Microbiology and Immunology, NextGen Precision Health Institute, University of Missouri, Columbia, USA.
- 3Department of Chemical Engineering, University of Michigan, Ann Arbor, USA.
Abstract
Islet transplantation can restore glycemic control in type 1 diabetes, yet heterogeneity of immune responses and transplant outcomes necessitates improved graft monitoring. Since transplanted islets are diffusely engrafted within the liver and inaccessible to biopsy, clinical monitoring relies on blood glucose and C-peptide, which change only after substantial graft injury. Here, we developed a synthetic immunological niche (IN) that captures graft-associated immune responses through serial subcutaneous biopsy. We evaluated the IN across murine syngeneic, allogeneic, and autoimmune islet transplant models, including CD40/CD154 blockade with anti-CD40L. The IN identified immune populations and transcriptomic signatures reflective of the graft and distinguished syngeneic from rejecting allografts. In anti-CD40L-treated allografts, the IN revealed innate immune programs characterized by macrophage- and dendritic cell-associated signatures linked to acceptance versus rejection, whereas untreated allografts showed stronger adaptive immune signatures. Longitudinal IN profiling detected inflammatory activation in accepted allografts, indicating persistent subclinical risk. Finally, in autoimmune allografts treated with anti-CD40L plus rapamycin, IN identified a 13-gene signature that separated early from late rejection and distinguished autoimmune- from alloimmune-associated rejection programs. These findings establish the IN as a platform for identification of early biomarkers of islet graft rejection before overt dysfunction, addressing an unmet need in islet transplant monitoring.
Related
- The Tell-Tale Heart ― Persistent Immune Activation in Histologically Rejection-Free Heart Transplant Recipients ―
- Targeting Vascular TRPV4 Activity Prevents Lung Transplant Ischemia-Reperfusion Injury and Rejection
- Diagnostic Performance of 99mTc-MAG3 Renal Scintigraphy for Acute Tubular Necrosis and Acute Rejection in Kidney Transplant Recipients with Suspected Graft Dysfunction During the First 90 Days: A Single-Center, Biopsy-Referenced Retrospective Study
- Alternate-Day Versus Consecutive-Day Anti-T Lymphocyte Globulin Induction in First Living-Donor Kidney Transplant Recipients at Low Immunological Risk: A Retrospective Cohort Study
- Peri-transplant eculizumab for preventing antibody-mediated rejection in kidney transplant recipients at high immunologic risk: a systematic review with design-stratified evidence synthesis
BibTeX
@article{roy2026immune,
title = {{Immune Biomarkers of Islet Transplant Rejection Revealed by Synthetic Immunological Niche.}},
author = {Jyotirmoy Roy and Abdalmonam Jadou Nejma and Mohammad Tarique and Amod Talekar and Shengli Wu and Brianna Ha and Yifei Jiang and Esma S Yolcu and Lonnie D Shea},
journal = {Advanced science (Weinheim, Baden-Wurttemberg, Germany)},
year = {2026},
month = oct,
doi = {10.1002/advs.78154},
url = {https://europepmc.org/article/MED/42850666},
note = {CC BY},
}
RIS
TY - JOUR
TI - Immune Biomarkers of Islet Transplant Rejection Revealed by Synthetic Immunological Niche.
AU - Jyotirmoy Roy
AU - Abdalmonam Jadou Nejma
AU - Mohammad Tarique
AU - Amod Talekar
AU - Shengli Wu
AU - Brianna Ha
AU - Yifei Jiang
AU - Esma S Yolcu
AU - Lonnie D Shea
PY - 2026
DA - 2026/10/08
JO - Advanced science (Weinheim, Baden-Wurttemberg, Germany)
DO - 10.1002/advs.78154
UR - https://europepmc.org/article/MED/42850666
AB - Islet transplantation can restore glycemic control in type 1 diabetes, yet heterogeneity of immune responses and transplant outcomes necessitates improved graft monitoring. Since transplanted islets are diffusely engrafted within the liver and inaccessible to biopsy, clinical monitoring relies on blood glucose and C-peptide, which change only after substantial graft injury. Here, we developed a synthetic immunological niche (IN) that captures graft-associated immune responses through serial subcutaneous biopsy. We evaluated the IN across murine syngeneic, allogeneic, and autoimmune islet transplant models, including CD40/CD154 blockade with anti-CD40L. The IN identified immune populations and transcriptomic signatures reflective of the graft and distinguished syngeneic from rejecting allografts. In anti-CD40L-treated allografts, the IN revealed innate immune programs characterized by macrophage- and dendritic cell-associated signatures linked to acceptance versus rejection, whereas untreated allografts showed stronger adaptive immune signatures. Longitudinal IN profiling detected inflammatory activation in accepted allografts, indicating persistent subclinical risk. Finally, in autoimmune allografts treated with anti-CD40L plus rapamycin, IN identified a 13-gene signature that separated early from late rejection and distinguished autoimmune- from alloimmune-associated rejection programs. These findings establish the IN as a platform for identification of early biomarkers of islet graft rejection before overt dysfunction, addressing an unmet need in islet transplant monitoring.
SN - 2198-3844
ER -